1938 related articles for article (PubMed ID: 33038433)
1. COVID-19: Discovery, diagnostics and drug development.
Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
[TBL] [Abstract][Full Text] [Related]
2. Perspectives for repurposing drugs for the coronavirus disease 2019.
Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
4. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.
Yadav M; Dhagat S; Eswari JS
Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661
[TBL] [Abstract][Full Text] [Related]
5. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
7. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
[TBL] [Abstract][Full Text] [Related]
8. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
9. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
12. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
13. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.
Borbone N; Piccialli G; Roviello GN; Oliviero G
Molecules; 2021 Feb; 26(4):. PubMed ID: 33668428
[TBL] [Abstract][Full Text] [Related]
15. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
16. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
[TBL] [Abstract][Full Text] [Related]
17. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
[TBL] [Abstract][Full Text] [Related]
18. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
[TBL] [Abstract][Full Text] [Related]
19. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
Marian AJ
Cardiovasc Pathol; 2021; 50():107278. PubMed ID: 32889088
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
